Enzalutamide (Xtandi®)

Common name: Enzalutamide
Brand name: Xtandi®
 

What is Enzalutamide?

Enzalutamide is an anti-androgen therapy that blocks the action of male hormones and is used to treat metastatic castration-resistant prostate cancer.

Enzalutamide has been approved for the following uses:
  • It is given to men who previously received docetaxel chemotherapy
  • It is also given to men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT)

How is Enzalutamide administered?

Enzalutamide is administered orally as a soft gelatin capsule.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. The table below lists some side effects experienced by those who received enzalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Back pain
  • Diarrhea
  • Joint pain
  • Headaches
  • Hot flashes
  • Muscle pain
  • Weakness


Is Enzalutamide covered in my province or territory?

Enzalutamide is covered by all provincial/territorial drug programs.

Xtandi Patient Assistance Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications to those who cannot afford to pay for their medicine.

Please call 1-855-898-2634 for more information and to see if you qualify for this program.

Enzalutamide has been approved for use by Health Canada and has been recommended for funding by the pan-Canadian Oncology Drug Review (pCODR) for both indications.

Read pCODR’s decisions for enzalutamide (xtandi®) below:

Enzalutamide - July 2013

Enzalutamide - June 2015

For more information on pCODR, please visit www.pcodr.ca

 
Last Updated: June 2018

Donate Now!






Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive